Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2017

View Archived Issues

BioAxone BioSciences awarded funding to develop sd-rxRNA compound for spinal cord injury

Novartis identifies potent, irreversible myeloperoxidase inhibitors for inflammation

Novel dual Axl/Mer inhibitors designed at Ono Pharmaceutical

First results of PATHWAY study on tezepelumab in severe asthma patients reported

Immunocore and Bill & Melinda Gates Foundation collaborate to develop TCR-based therapeutics

Pluristem Therapeutics' PLX-PAD given FDA fast track status for critical limb ischemia

Emcure Pharmaceuticals discovers novel IDO-1, TDO inhibitors

Novel interleukin-1 receptor-associated kinase 4 inhibitors identified at Bayer

Galapagos presents new sphingosine 1-phosphate receptor antagonists

New serine protease HTRA1 inhibitors disclosed by Roche

CSIR identifies novel aurone alkaloids for tuberculosis

DelMar Pharmaceuticals cleared by FDA to begin clinical studies of VAL-083

Pain Therapeutics receives NIH grants to support Alzheimer's and pain programs

EMA committee recommends approval of 10 mg rivaroxaban for extended prevention of VTE

Moderna Therapeutics reports new development candidates and pipeline progress

Innovate UK awards new funding to Cypralis to develop inhibitors of pancreatic fibrosis

NCI SBIR grant to support phase III study of SGX-301 in CTCL

Phase III MURANO study of venetoclax/rituximab combo in CLL meets primary endpoint

Dupilumab given FDA orphan drug status for eosinophilic esophagitis

Inovio Pharmaceuticals cleared to begin trial of MERS vaccine

New feline model of heart failure with preserved ejection fraction described

FDA approves Trelegy Ellipta for COPD

Cancer Prevention Pharmaceuticals's lead drug for FAP granted fast track status in U.S.

Autolus begins phase I/II studies of AUTO-3 for B-cell ALL and DLBCL

G3 Pharmaceuticals starts research and development program to pursue novel galectin-3 inhibitors

FDA accepts Camurus' NDA for CAM-2038 buprenorphine depots

Bristol-Myers Squibb describes discovery of phase I anti-PD-L1 candidate BMS-986189

FDA approves Xhance for treatment of nasal polyps

Arrowhead updates status of pipeline

BELLUS Health's BLU-5937 significantly reduces cough in preclinical models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...